Skip to main content
Erschienen in: Clinical and Experimental Nephrology 2/2012

01.04.2012 | Special Report

Chronic kidney disease prevention—a challenge for Asian countries: report of the Third Asian Forum of Chronic Kidney Disease Initiatives

verfasst von: Jer-Ming Chang, Shang-Jyh Hwang, Yusuke Tsukamoto, Hung-Chun Chen

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

As an independent meeting, the third Asian Forum of Chronic Kidney Disease Initiatives was held on April 18–19, 2009, in Kaohsiung, Taiwan. Nearly 700 participants from 17 countries attended and 78 posters were presented. To begin with, status quo in Asia and in Taiwan was briefed, followed by Theme 1A “Special Epidemiology and Risk Factors”, during which the interrelations between chronic kidney disease (CKD) and use of herbs, low birth weight, infections, and immunoglobulin A (IgA) nephropathy were discussed. Theme 1B dealt with both cardiovascular and renal outcomes of CKD patients. In Theme 2, five presenters from different countries shared their experiences on “Cost-effectiveness of Community-based or Nationwide CKD Prevention Programs”. In between the conference themes, three international and integrative works—Kidney Disease Improving Global Outcomes, the World Kidney Day, and Kidney Early Evaluation Program—were presented and possible implications for Asia were suggested. Theme 3 was initiated with a thorough discussion on “Equation of the Estimated Glomerular Filtration Rate for Asians” and the preliminary results of a cross-country study were presented. In Theme 4, the care plan, strategies, and outcomes of timely initiation of dialysis in different countries were discussed. The final session started with a concise summary of all speeches and ended with a position statement.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Just PM, de Charro FT, Tschosik EA, Noe LL, Bhattacharyya SK, Riella MC. Reimbursement and economic factors influencing dialysis modality choice around the world. Nephrol Dial Transplant. 2008;23:2365–73.PubMedCrossRef Just PM, de Charro FT, Tschosik EA, Noe LL, Bhattacharyya SK, Riella MC. Reimbursement and economic factors influencing dialysis modality choice around the world. Nephrol Dial Transplant. 2008;23:2365–73.PubMedCrossRef
2.
Zurück zum Zitat Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462293 adults in Taiwan. Lancet. 2008;371:2173–82.PubMedCrossRef Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462293 adults in Taiwan. Lancet. 2008;371:2173–82.PubMedCrossRef
3.
Zurück zum Zitat Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–47.PubMedCrossRef Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–47.PubMedCrossRef
4.
Zurück zum Zitat Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007;11:156–63.PubMedCrossRef Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007;11:156–63.PubMedCrossRef
5.
Zurück zum Zitat Harris D, Thomas M, Johnson D, Nicholls K, Gillin A. The CARI guidelines. Prevention of progression of kidney disease. Nephrology. 2006;11(Suppl 1):S2–197.PubMedCrossRef Harris D, Thomas M, Johnson D, Nicholls K, Gillin A. The CARI guidelines. Prevention of progression of kidney disease. Nephrology. 2006;11(Suppl 1):S2–197.PubMedCrossRef
6.
Zurück zum Zitat Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, et al. Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis. 2007;50:927–37.PubMedCrossRef Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, et al. Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis. 2007;50:927–37.PubMedCrossRef
7.
Zurück zum Zitat Tsukamoto Y, Wang H, Becker G, Chen HC, Han DS, Harris D, et al. Report of the Asian Forum of Chronic Kidney Disease Initiative (AFCKDI) 2007. “Current status and perspective of CKD in Asia”: diversity and specificity among Asian countries. Clin Exp Nephrol. 2009;13:249–56.PubMedCrossRef Tsukamoto Y, Wang H, Becker G, Chen HC, Han DS, Harris D, et al. Report of the Asian Forum of Chronic Kidney Disease Initiative (AFCKDI) 2007. “Current status and perspective of CKD in Asia”: diversity and specificity among Asian countries. Clin Exp Nephrol. 2009;13:249–56.PubMedCrossRef
8.
Zurück zum Zitat Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2937–44.PubMedCrossRef Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2937–44.PubMedCrossRef
9.
Zurück zum Zitat Yamagata K, Iseki K, Nitta K, Imai H, Iino Y, Matsuo S, et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol. 2008;12:1–8.PubMedCrossRef Yamagata K, Iseki K, Nitta K, Imai H, Iino Y, Matsuo S, et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol. 2008;12:1–8.PubMedCrossRef
10.
Zurück zum Zitat Kang YS, Han KH, Han SY, Kim HK, Cha DR. Characteristics of population with normal serum creatinine impaired renal function and the validation of a MDRD formula in a healthy general population. Clin Nephrol. 2005;63:258–66.PubMed Kang YS, Han KH, Han SY, Kim HK, Cha DR. Characteristics of population with normal serum creatinine impaired renal function and the validation of a MDRD formula in a healthy general population. Clin Nephrol. 2005;63:258–66.PubMed
11.
Zurück zum Zitat Ito J, Dung DT, Vuong MT, Tuyen do G, Vinh le D, Huong NT, et al. Impact and perspective on chronic kidney disease in an Asian developing country: a large-scale survey in North Vietnam. Nephron Clin Pract. 2008;109:c25–32.PubMedCrossRef Ito J, Dung DT, Vuong MT, Tuyen do G, Vinh le D, Huong NT, et al. Impact and perspective on chronic kidney disease in an Asian developing country: a large-scale survey in North Vietnam. Nephron Clin Pract. 2008;109:c25–32.PubMedCrossRef
12.
Zurück zum Zitat Tsukamoto Y, Jha V, Backer G, Chen HC, Perkovic V, Prodjosudjadi W, et al. A challenge to chronic kidney disease in Asia: the report of the second Asian Forum of Chronic Kidney Disease Initiative. Nephrology. 2010;15:248–52.PubMedCrossRef Tsukamoto Y, Jha V, Backer G, Chen HC, Perkovic V, Prodjosudjadi W, et al. A challenge to chronic kidney disease in Asia: the report of the second Asian Forum of Chronic Kidney Disease Initiative. Nephrology. 2010;15:248–52.PubMedCrossRef
13.
Zurück zum Zitat Hsu CC, Hwang SJ, Wen CP, Chang HY, Chen T, Shiu RS, et al. High prevalence and low awareness of CKD in Taiwan: a study on the relationship between serum creatinine and awareness from a nationally representative survey. Am J Kidney Dis. 2006;48:727–38.PubMedCrossRef Hsu CC, Hwang SJ, Wen CP, Chang HY, Chen T, Shiu RS, et al. High prevalence and low awareness of CKD in Taiwan: a study on the relationship between serum creatinine and awareness from a nationally representative survey. Am J Kidney Dis. 2006;48:727–38.PubMedCrossRef
14.
Zurück zum Zitat Tsai JC, Chen SC, Hwang SJ, Chang JM, Lin MY, Chen HC. Prevalence and risk factors for CKD in spouses and relatives of hemodialysis patients. Am J Kidney Dis. 2010;55:856–66.PubMedCrossRef Tsai JC, Chen SC, Hwang SJ, Chang JM, Lin MY, Chen HC. Prevalence and risk factors for CKD in spouses and relatives of hemodialysis patients. Am J Kidney Dis. 2010;55:856–66.PubMedCrossRef
15.
Zurück zum Zitat Lee JJ, Lin MY, Yang YH, Lu SN, Chen HC, Hwang SJ. Association of hepatitis C and B viral infection with chronic kidney disease in Taiwanese endemic area: a cross-sectional study. Am J Kidney Dis. 2010;56:23–31.PubMedCrossRef Lee JJ, Lin MY, Yang YH, Lu SN, Chen HC, Hwang SJ. Association of hepatitis C and B viral infection with chronic kidney disease in Taiwanese endemic area: a cross-sectional study. Am J Kidney Dis. 2010;56:23–31.PubMedCrossRef
16.
Zurück zum Zitat Soderland P, Lovekar S, Weiner DE, Brooks DR, Kaufman JS. Chronic kidney disease associated with environmental toxins and exposures. Adv Chronic Kidney Dis. 2010;17:254–64.PubMedCrossRef Soderland P, Lovekar S, Weiner DE, Brooks DR, Kaufman JS. Chronic kidney disease associated with environmental toxins and exposures. Adv Chronic Kidney Dis. 2010;17:254–64.PubMedCrossRef
17.
Zurück zum Zitat Newsome CA, Shiell AW, Fall CH, Phillips DI, Shier R, Law CM. Is birth weight related to later glucose and insulin metabolism? A systematic review. Diabet Med. 2003;20:339–48.PubMedCrossRef Newsome CA, Shiell AW, Fall CH, Phillips DI, Shier R, Law CM. Is birth weight related to later glucose and insulin metabolism? A systematic review. Diabet Med. 2003;20:339–48.PubMedCrossRef
18.
Zurück zum Zitat Davies AA, Smith GD, May MT, Ben-Shlomo Y. Association between birth weight and blood pressure is robust, amplifies with age, and may be underestimated. Hypertension. 2006;48:431–6.PubMedCrossRef Davies AA, Smith GD, May MT, Ben-Shlomo Y. Association between birth weight and blood pressure is robust, amplifies with age, and may be underestimated. Hypertension. 2006;48:431–6.PubMedCrossRef
19.
Zurück zum Zitat Luyckx VA, Brenner BM. Low birth weight, nephron number, and kidney disease. Kidney Int. 2005;68(Suppl 97):S68–77.CrossRef Luyckx VA, Brenner BM. Low birth weight, nephron number, and kidney disease. Kidney Int. 2005;68(Suppl 97):S68–77.CrossRef
20.
Zurück zum Zitat Bagby SP. Developmental origins of renal disease: should nephron protection begin at birth? Clin J Am Soc Nephrol. 2009;4:10–3.PubMedCrossRef Bagby SP. Developmental origins of renal disease: should nephron protection begin at birth? Clin J Am Soc Nephrol. 2009;4:10–3.PubMedCrossRef
21.
Zurück zum Zitat Hoy WE, Hughson MD, Bertram JF, Douglas-Denton R, Amann K. Nephron number, hypertension, renal disease, and renal failure. J Am Soc Nephrol. 2005;16:2557–64.PubMedCrossRef Hoy WE, Hughson MD, Bertram JF, Douglas-Denton R, Amann K. Nephron number, hypertension, renal disease, and renal failure. J Am Soc Nephrol. 2005;16:2557–64.PubMedCrossRef
22.
Zurück zum Zitat Yang CW. Leptospirosis renal disease: understanding the initiation by Toll-like receptors. Kidney Int. 2007;72:918–25.PubMedCrossRef Yang CW. Leptospirosis renal disease: understanding the initiation by Toll-like receptors. Kidney Int. 2007;72:918–25.PubMedCrossRef
23.
Zurück zum Zitat Gluba A, Banach M, Hannam S, Mikhailidis DP, Sakowicz A, Rysz J. The role of Toll-like receptors in renal diseases. Nat Rev Nephrol. 2010;6:224–35.PubMedCrossRef Gluba A, Banach M, Hannam S, Mikhailidis DP, Sakowicz A, Rysz J. The role of Toll-like receptors in renal diseases. Nat Rev Nephrol. 2010;6:224–35.PubMedCrossRef
24.
Zurück zum Zitat Tumlin JA, Madaio MP, Hennigar R. Idiopathic IgA nephropathy: pathogenesis, histopathology, and therapeutic options. Clin J Am Soc Nephrol. 2007;2:1054–61.PubMedCrossRef Tumlin JA, Madaio MP, Hennigar R. Idiopathic IgA nephropathy: pathogenesis, histopathology, and therapeutic options. Clin J Am Soc Nephrol. 2007;2:1054–61.PubMedCrossRef
25.
Zurück zum Zitat Goto M, Wakai K, Kawamura T, Ando M, Endoh M, Tomino Y. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transplant. 2009;24:3068–74.PubMedCrossRef Goto M, Wakai K, Kawamura T, Ando M, Endoh M, Tomino Y. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transplant. 2009;24:3068–74.PubMedCrossRef
26.
Zurück zum Zitat Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53–61.PubMedCrossRef Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53–61.PubMedCrossRef
27.
Zurück zum Zitat Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307–15.PubMedCrossRef Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307–15.PubMedCrossRef
28.
Zurück zum Zitat McCullough PA, Agarwal M, Agrawal V. Review article: Risks of coronary artery calcification in chronic kidney disease: do the same rules apply? Nephrology. 2009;14:428–36.PubMedCrossRef McCullough PA, Agarwal M, Agrawal V. Review article: Risks of coronary artery calcification in chronic kidney disease: do the same rules apply? Nephrology. 2009;14:428–36.PubMedCrossRef
29.
Zurück zum Zitat Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res. 2004;95:560–7.PubMedCrossRef Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res. 2004;95:560–7.PubMedCrossRef
30.
Zurück zum Zitat Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17:1181–91.PubMedCrossRef Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17:1181–91.PubMedCrossRef
31.
Zurück zum Zitat Iseki K, Iseki C, Ikemiya Y, Fukiyama K. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int. 1996;49:800–5.PubMedCrossRef Iseki K, Iseki C, Ikemiya Y, Fukiyama K. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int. 1996;49:800–5.PubMedCrossRef
32.
Zurück zum Zitat Iseki K, Tozawa M, Iseki C, Takishita S, Ogawa Y. Demographic trends in the Okinawa Dialysis Study (OKIDS) registry (1971–2000). Kidney Int. 2002;61:668–75.PubMedCrossRef Iseki K, Tozawa M, Iseki C, Takishita S, Ogawa Y. Demographic trends in the Okinawa Dialysis Study (OKIDS) registry (1971–2000). Kidney Int. 2002;61:668–75.PubMedCrossRef
34.
Zurück zum Zitat Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003;290:3101–4.PubMedCrossRef Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003;290:3101–4.PubMedCrossRef
35.
Zurück zum Zitat Wei SY, Chang YY, Mau LW, Lin MY, Chiu HC, Tsai JC, et al. Chronic kidney disease care program improves quality of pre-end-stage renal disease care and reduces medical costs. Nephrology. 2010;15:108–15.PubMedCrossRef Wei SY, Chang YY, Mau LW, Lin MY, Chiu HC, Tsai JC, et al. Chronic kidney disease care program improves quality of pre-end-stage renal disease care and reduces medical costs. Nephrology. 2010;15:108–15.PubMedCrossRef
36.
Zurück zum Zitat Uhlig K, Macleod A, Craig J, Lau J, Levey AS, Levin A, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;70:2058–65.PubMed Uhlig K, Macleod A, Craig J, Lau J, Levey AS, Levin A, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;70:2058–65.PubMed
37.
Zurück zum Zitat Strippoli GF, Craig JC, Schena FP. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol. 2004;15:411–9.PubMedCrossRef Strippoli GF, Craig JC, Schena FP. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol. 2004;15:411–9.PubMedCrossRef
38.
Zurück zum Zitat Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–53.PubMedCrossRef Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–53.PubMedCrossRef
39.
Zurück zum Zitat McCullough PA, Vassalotti JA, Collins AJ, Chen SC, Bakris GL. National Kidney Foundation’s Kidney Early Evaluation Program (KEEP) annual data report 2009: executive summary. Am J Kidney Dis. 2010;55(3 Suppl 2):S1–3.PubMedCrossRef McCullough PA, Vassalotti JA, Collins AJ, Chen SC, Bakris GL. National Kidney Foundation’s Kidney Early Evaluation Program (KEEP) annual data report 2009: executive summary. Am J Kidney Dis. 2010;55(3 Suppl 2):S1–3.PubMedCrossRef
40.
Zurück zum Zitat Levey AS, Greene T, Schluchter MD, Cleary PA, Teschan PE, Lorez RA, et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol. 1003;4:1159–71. Levey AS, Greene T, Schluchter MD, Cleary PA, Teschan PE, Lorez RA, et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol. 1003;4:1159–71.
41.
Zurück zum Zitat Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006;17:2275–84.PubMedCrossRef Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006;17:2275–84.PubMedCrossRef
42.
Zurück zum Zitat Burgess E, Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S, SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol. 2009;20:893–900.PubMedCrossRef Burgess E, Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S, SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol. 2009;20:893–900.PubMedCrossRef
43.
Zurück zum Zitat Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol. 2007;18:1889–98.PubMedCrossRef Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol. 2007;18:1889–98.PubMedCrossRef
44.
Zurück zum Zitat Chen SC, Chang JM, Chou MC, Lin MY, Chen JH, Sun JH, et al. Slowing renal function decline in chronic kidney disease patients after nephrology referral. Nephrology. 2008;13:730–6.PubMedCrossRef Chen SC, Chang JM, Chou MC, Lin MY, Chen JH, Sun JH, et al. Slowing renal function decline in chronic kidney disease patients after nephrology referral. Nephrology. 2008;13:730–6.PubMedCrossRef
45.
Zurück zum Zitat Chen SC, Hwang SJ, Tsai JC, Liu WC, Hwang SC, Chou MC, et al. Early nephrology referral is associated with prolonged survival in hemodialysis patients even after exclusion of lead-time bias. Am J Med Sci. 2010;339:123–6.PubMedCrossRef Chen SC, Hwang SJ, Tsai JC, Liu WC, Hwang SC, Chou MC, et al. Early nephrology referral is associated with prolonged survival in hemodialysis patients even after exclusion of lead-time bias. Am J Med Sci. 2010;339:123–6.PubMedCrossRef
46.
Zurück zum Zitat Yu AW, Chau KF, Ho YW, Li PK. Development of the “peritoneal dialysis first” model in Hong Kong. Perit Dial Int. 2007;27(Suppl 2):S53–5.PubMed Yu AW, Chau KF, Ho YW, Li PK. Development of the “peritoneal dialysis first” model in Hong Kong. Perit Dial Int. 2007;27(Suppl 2):S53–5.PubMed
47.
Zurück zum Zitat Annual Report of the Global Budget Payment System for outpatient dialysis therapy. Bureau of National Health Insurance, Department of Health, Taiwan; 2010. Annual Report of the Global Budget Payment System for outpatient dialysis therapy. Bureau of National Health Insurance, Department of Health, Taiwan; 2010.
48.
Zurück zum Zitat Nakai S, Masakane I, Shigematsu T, Hamano T, Yamagata K, Watanabe Y, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2007). Ther Apher Dial. 2009;13:457–504.PubMedCrossRef Nakai S, Masakane I, Shigematsu T, Hamano T, Yamagata K, Watanabe Y, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2007). Ther Apher Dial. 2009;13:457–504.PubMedCrossRef
49.
Zurück zum Zitat Stel VS, Kramer A, Zoccali C, Jager KJ. The 2007 ERA-EDTA Registry Annual Report—a Précis. J Nephrol. 2009;22(1–12):9. Stel VS, Kramer A, Zoccali C, Jager KJ. The 2007 ERA-EDTA Registry Annual Report—a Précis. J Nephrol. 2009;22(1–12):9.
50.
Zurück zum Zitat Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, The IDEAL Study, et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med. 2010;12(363):609–19.CrossRef Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, The IDEAL Study, et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med. 2010;12(363):609–19.CrossRef
51.
Zurück zum Zitat Hwang SJ, Yang WC, Lin MY, Mau LW, Taiwan Society of Nephrology. Impact of the clinical conditions at dialysis initiation on mortality in incident haemodialysis patients: a national cohort study in Taiwan. Nephrol Dial Transplant. 2010;25:2616–24.PubMedCrossRef Hwang SJ, Yang WC, Lin MY, Mau LW, Taiwan Society of Nephrology. Impact of the clinical conditions at dialysis initiation on mortality in incident haemodialysis patients: a national cohort study in Taiwan. Nephrol Dial Transplant. 2010;25:2616–24.PubMedCrossRef
Metadaten
Titel
Chronic kidney disease prevention—a challenge for Asian countries: report of the Third Asian Forum of Chronic Kidney Disease Initiatives
verfasst von
Jer-Ming Chang
Shang-Jyh Hwang
Yusuke Tsukamoto
Hung-Chun Chen
Publikationsdatum
01.04.2012
Verlag
Springer Japan
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 2/2012
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-012-0592-8

Weitere Artikel der Ausgabe 2/2012

Clinical and Experimental Nephrology 2/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.